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Introduction {#sec005}
============

Type 2 diabetes mellitus (T2DM) is a chronic and progressive disease associated with both microvascular and macrovascular complications \[[@pone.0153502.ref001]\]. The risk of cardiovascular (CV) disease is known to be higher in people with diabetes compared to those without diabetes \[[@pone.0153502.ref002]\] and CV disease accounts for excess mortality in T2DM \[[@pone.0153502.ref003]\].

In the assessment of CV risks, glycated hemoglobin control was conventionally thought as related to CV risk owing to the United Kingdom Prospective Diabetes Study (UKPDS) 10-year follow-up study. The study demonstrated a significant reduction in myocardial infarction (MI) and all-cause mortality in overweight newly diagnosed patients with T2DM in intensive glycemic control with metformin \[[@pone.0153502.ref004]\]. Stemming from these results, improved glycemic control has been traditionally thought to reduce the risk of the microvascular complications of diabetes.

However, more recently, the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) and the Veterans Affairs Diabetes Trial (VADT) did not find significant beneficial effects of intensive glucose control in nonfatal MI, nonfatal stroke, and overall CV mortality \[[@pone.0153502.ref005], [@pone.0153502.ref006]\]. Taken together, the results from clinical trials introduced controversy about the effect of glycemic control on CV disease risk, and uncertainty remains regarding whether any particular glucose lowering strategy actually lowers CV risk.

A recent perspective article published in *New England Journal of Medicine* by the US Food and Drug Administration (FDA) advisory committee members stated that the optimal approach to the reduction of cardiovascular risk in diabetes patients should focus on the management of standard cardiovascular risk factors rather than intensive glycemic control.\[[@pone.0153502.ref007]\]

From a drug safety perspective, there has been increasing concern and need of assurance regarding antihyperglycemic agents' cardiovascular safety. After the concerns raised in 2008 about the cardiac safety of rosiglitazone, the FDA issued an updated Guidance for Industry that required pre and post approval studies to rule out excess cardiovascular risk of any new antidiabetic drug. \[[@pone.0153502.ref008]\].

In four previous CV trials on incretins \[[@pone.0153502.ref009]--[@pone.0153502.ref012]\], there was no evidence of an increase or decrease in the number of major adverse cardiovascular events but there were safety concerns regarding a possible elevated risk in hospitalization for heart failure.

Hence, there is a need for a rigorous evaluation of the cardiovascular safety of GLP-1 receptor agonists and DPP-4 inhibitors. In the absence of head-to-head trials, this analysis may provide valuable insight into the comparative outcomes of incretin overall class versus placebo or active control.

As a part of this study, we conducted a systematic review of randomized and controlled studies to provide a comprehensive assessment regarding the risk of cardiovascular diseases associated with DPP-4 inhibitors and GLP-1 receptor agonists compared to placebo or other antihyperglycaemic agents.

Materials and Methods {#sec006}
=====================

Data sources and searches {#sec007}
-------------------------

We conducted a search in MEDLINE (via PubMed), EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to August 2014. We developed a search strategy using MeSH and free text terms. Study type was restricted to randomized controlled trials, controlled trials, clinical trial, controlled clinical trial, controlled studies and clinical studies in humans.

Study selection {#sec008}
---------------

We included studies that (1) enrolled adult patients (of at least 18 years of age) with T2DM with no other complications, (2) compared DPP-4 inhibitors or GLP-1 receptor agonists against placebo (placebo-controlled) or other antihyperglycemic agents (active-controlled), (3) duration of at least 12 weeks, and (4) had explicit reported events of predefined CV outcomes. Trials with shorter duration were excluded because of inadequate time to assess changes in glycemic efficacy, since hemoglobin A1~c~ reflects glycemia during previous 3 months \[[@pone.0153502.ref013]\].

We followed systematic approach to only include studies with patients who have no other complications at baseline in order to target the study group as primary prevention population and compare the CV effect of incretin in this patient group who are low CV risk patients without significant cardiovascular disease comorbidities or significant laboratory changes. To be classified as T2DM with no other complications, we ensured that the patients included had no underlying diseases at baseline. We also collected information on CV and renal biomarkers such as systolic blood pressure (SBP), diastolic blood pressure (DBP), HDL (high density lipoprotein) cholesterol, LDL (low density lipoprotein) cholesterol, total cholesterol (TC), triglycerides (TG), creatinine clearance (CrCl), serum creatinine (SCr), and glomerular filtration rate (GFR); we reviewed baseline level of each biomarker to exclude any above normal results. We excluded patients with baseline hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg \[[@pone.0153502.ref014]\]) or history of hypertension or an antihypertensive treatment, dyslipidemia (HDL \< 40 mg/dL, LDL \> 130 mg/dL, TC \> 200 mg/dL, TG \> 150 mg/dL \[[@pone.0153502.ref015]\]), impaired renal function (CrCl \< 30 mL/min, SCr \> 1.2 mg/dL, GFR \< 30 mL/min\[[@pone.0153502.ref016]\]) or history of renal disease of disease treatment, and history of other vascular diseases or disease treatment.

The predefined CV outcomes were classified as described below. This classification was reviewed by a cardiologist.

1.  Death: cardiac death, sudden death, all causes of death.

2.  Heart failure: heart failure, cardiac failure, cardiac myopathy.

3.  Hypertension: hypertension, blood pressure change, hypertensive crisis.

4.  Vascular disorders: dyslipidemia, hyperlipidemia, stroke, thrombosis, deep vein thrombosis, arteriosclerosis, raised triglycerides, raised LDL, decreased HDL, lipidemia, hypercholesterolemia, aortic valve sclerosis.

5.  Coronary artery disease: angina, myocardial infarction, ischemia, revascularization, acute coronary syndrome, coronary artery blockage, ST elevation myocardial infarction, non-ST elevation myocardial infarction coronary artery stenosis, coronary artery disease.

6.  Arrhythmia: arrhythmia, tachycardia, bradycardia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, cardio-respiratory arrest, palpitation, ventricular extra systoles, supraventricular extra systoles, left bundle branch block.

7.  Other/ Non-specified: chest pain, hypotension, cardiomegaly, cerebral infarction, syncope.

Data extraction and quality assessment {#sec009}
--------------------------------------

Publications retrieved from three search engines were imported into the reference management software (Endnote^®^ X6, X7; Thomson Reuters, New York, NY). After removing duplicate results, two reviewers (KJY, CMJ) independently screened all titles, abstracts, and full texts according to the study process. Any discrepancies were resolved by discussion and adjudication by the third reviewer (YSW).

For quality assessment, we used Cochrane Collaboration's tool \[[@pone.0153502.ref017]\] to assess the risk of bias of the included trials. We considered random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, and incomplete outcome data and evaluated whether the adjudication of CV events was carried out. Risk of bias was evaluated at three levels: 'low (low risk of bias)', 'high (high risk of bias)' and 'unclear'. The result was not used as a criterion for the selection of trials, but only for descriptive purposes.

To assess possible publication or disclosure bias we used funnel plots, the Begg adjusted rank correlation test \[[@pone.0153502.ref018]\]. Asymmetry in a funnel plot (also known as small study effects \[[@pone.0153502.ref019]\]) is potentially indicative of publication biases.

All analyses were performed using Review Manager 5.3 software (RevMan version 5.3; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration).

Data synthesis {#sec010}
--------------

We further collected information from the selected trials on study characteristics (study design, study duration, total study population, total safety population), baseline patient characteristics (mean age, percentage of male, mean duration of diabetes, mean body mass index \[BMI\], mean fasting plasma glucose \[FPG\]), interventions (incretin treatment, control treatment, dose, drug used across groups, mode of therapy), duration of treatment and number of CV events reported.

For extension trials, we used data from the longest follow-up. If treatment assignments were exchanged or both arms were assigned to incretin therapy in the extension period, we collected data before that point, if provided.

Trials were excluded if intervention and comparator groups were both based on incretin therapy with no placebo or other antihyperglycemic group (e.g. sitagliptin vs. exenatide trial). If placebo and other antihyperglycemic agent group were both included or multiple incretin arms were included in the study, we reconstructed the study arms into incretin vs. comparator arm.

Add-on therapies included other oral antihyperglycemic agents (i.e., sulphonylureas, thiazolidinediones and biguanides) and injectable therapies (i.e., insulin) co-administered with the incretin-based therapies or the comparator arm (combination therapy). If there was at least one arm treated with a combination therapy, trial was classified as add-on therapy trial.

Active controlled studies were those compared with other antihyperglycaemic agents and placebo controlled studies were trials where comparator arm was placebo.

Data analysis {#sec011}
-------------

We assessed heterogeneity between studies using the χ^2^ test and I^2^ statistic with a significance threshold for α of 0.10 \[[@pone.0153502.ref020]\]. We report the results of fixed-effect model because generally the heterogeneity data was not present in the studies included. We conducted a sensitivity analysis using an alternative heterogeneity consideration model on those subgroup analyses with high heterogeneity. We pooled trials using the Mantel-Haenszel method, since the number of CV events is dichotomous variables, Mantel-Haenszel odds ratio (MH-OR) with 95% confidence interval was calculated for all CV events defined. We performed a primary analysis to find out the overall incretin effect on predefined general CV risk. Furthermore, diverse subgroup analyses were performed: type of incretin (DPP-4 inhibitors vs. control, GLP-1 receptor agonist vs. control); type of control with mode of therapy (placebo controlled in mono therapy, placebo controlled in add-on therapy, active controlled in mono therapy, active controlled in add-on therapy); classified CV outcomes; and individual incretin agents.

Results {#sec012}
=======

Our search yielded 4,206 potentially relevant reports. After screening titles and abstracts, we retrieved 1,600 reports for full text screening. A total of 75 studies were eligible for final inclusion comprising 45,648 patients ([Fig 1](#pone.0153502.g001){ref-type="fig"}). The median duration of the 75 trials---all industry funded---was 35 weeks (ranging from: 12 to 112 weeks). The trials enrolled a mean of 608 (ranging from 36 to 3,118 patients), and the population for safety analysis accounted for a mean of 610 patients (ranging from 36 to 3,099). The mean age was 56.1 years old and 54.1% were males. The mean BMI was 30.3 kg/m^2^ (ranging from 24.1 to 33.9 kg/m^2^), the mean baseline HbA1~c~ was 8.3% (ranging from 6.6 to 11.4%), the mean FPG was 9.5 mmol/L (ranging from 6.9 to 12.2 mmol/L), and the mean duration of diabetes was 6.5 years (ranging from 1.3 to 12.6 years). The average value was calculated excluding those not reported ([Table 1](#pone.0153502.t001){ref-type="table"}).The intervention characteristics and number of CV events reported in each trial are summarized in [Table 2](#pone.0153502.t002){ref-type="table"}. Fifty-eight trials tested DPP-4 inhibitors, 16 tested GLP-1 receptor agonists, and one tested both agents ([Table 2](#pone.0153502.t002){ref-type="table"}).

![Flow chart of article selection (PRISMA flow diagram).](pone.0153502.g001){#pone.0153502.g001}

10.1371/journal.pone.0153502.t001

###### Characteristics of included trials of incretin treatment in patients with type 2 diabetes mellitus.

![](pone.0153502.t001){#pone.0153502.t001g}

  Author (year)                                        Total population   Safety population   Study duration (weeks)   Mean Age (years)   Male (%)   Mean diabetes duration (years)                    Mean BMI (kg/m^2^)   Mean HbA1C (%)                                      MeanFPG (mmol/L)
  ---------------------------------------------------- ------------------ ------------------- ------------------------ ------------------ ---------- ------------------------------------------------- -------------------- --------------------------------------------------- ------------------
  Aschner 2006\[[@pone.0153502.ref037]\]               741                741                 24                       54.2               51.7       4.4                                               30.5                 8.0                                                 9.7
  Aschner 2010\[[@pone.0153502.ref038]\]               1,050              1,050               24                       56.0               46.0       2.4                                               30.8                 7.2                                                 7.9
  Barnett 2012\[[@pone.0153502.ref039]\]               455                455                 24                       57.2               41.7       11.9                                              32.3                 8.7                                                 9.6
  Bergenstal 2009\[[@pone.0153502.ref040]\]            372                372                 24                       52.6               48.1       9.0                                               33.8                 10.2                                                11.3
  Blonde 2009\[[@pone.0153502.ref041]\]                2,664              2,627               12                       55.6               51.8       5.1                                               32.4                 8.0                                                 9.3
  Bolli 2009\[[@pone.0153502.ref042]\]                 576                576                 52                       56.6               62.9       6.4                                               32.2                 8.4                                                 10.9
  Bosi 2007\[[@pone.0153502.ref043]\]                  416                541                 24                       54.2               57.4       6.3                                               32.7                 8.4                                                 9.9
  Bosi 2009\[[@pone.0153502.ref022]\]                  1,179              1,171               24                       52.8               58         2.0                                               31.2                 8.7                                                 10.4
  Chacra 2011\[[@pone.0153502.ref044]\]                768                768                 76                       55.1               45.1       6.9                                               29                   8.4                                                 9.6
  Del 2011\[[@pone.0153502.ref045]\]                   503                503                 24                       55.7               48.3       NR                                                29.1                 8                                                   8.9
  Dobs 2013\[[@pone.0153502.ref046]\]                  262                260                 54                       54.5               54.8       9.3                                               30.3                 8.8                                                 10.1
  Filozof 2010\[[@pone.0153502.ref047]\]               1,007              1,007               52                       59.5               52         6.6                                               31                   8.5                                                 10.7
  Fonesca 2012(2)\[[@pone.0153502.ref048]\]            361                361                 12                       53.7               51.5       1.3                                               31.9                 8.0                                                 9.0
  Fonseca 2012\[[@pone.0153502.ref049]\]               282                282                 18                       55.4               46.1       6.2                                               30.9                 8.3                                                 9.0
  Fonseca 2013\[[@pone.0153502.ref050]\]               313                313                 26                       56.0               62.3       9.8                                               29.9                 8.8                                                 9.8
  Forst 2010\[[@pone.0153502.ref051]\]                 333                333                 12                       60.0               58         7                                                 31.9                 8.3                                                 10.3
  Gallwitz 2012\[[@pone.0153502.ref052]\]              1,029              1019                48                       56.0               54.0       5.7                                               32.5                 7.5                                                 8.8
  Gallwitz 2012(2)\[[@pone.0153502.ref023]\]           1,551              1551                104                      59.8               60.5       715(47.1%)[\*](#t001fn002){ref-type="table-fn"}   30.2                 7.7                                                 9.1
  Garber 2007\[[@pone.0153502.ref053]\]                398                462                 24                       54.3               50.0       4.7                                               32.4                 8.7                                                 10.1
  Garber 2008\[[@pone.0153502.ref054]\]                408                515                 24                       58.2               59.0       7.2                                               31.3                 8.5                                                 10.4
  Garber 2011\[[@pone.0153502.ref055]\]                745                745                 104                      53.0               50.0       5.4                                               33.1                 8.3                                                 9.4
  Goke 2013\[[@pone.0153502.ref056]\]                  858                858                 104                      57.6               51.8       5.4                                               31.4                 7.7                                                 9.0
  Goodman 2009\[[@pone.0153502.ref057]\]               370                370                 24                       54.8               57.5       NR                                                31.5                 8.6                                                 10.9
  Grunberge 2012\[[@pone.0153502.ref058]\]             164                164                 12                       56.6               45.1       3.9                                               32.1                 7.2                                                 NR
  Haak 2012\[[@pone.0153502.ref059]\]                  791                791                 24                       55.3               53.8       562(74.3%)[\*](#t001fn002){ref-type="table-fn"}   29.1                 8.7                                                 10.8
  Henry 2011\[[@pone.0153502.ref021]\]                 36                 36                  12                       55.6               38.9       3.1                                               32.9                 6.8                                                 7.1
  Hollander 2011\[[@pone.0153502.ref060]\]             565                565                 76                       54.0               49.6       5.2                                               30.0                 8.3                                                 9.0
  Inagaki 2012\[[@pone.0153502.ref061]\]               427                427                 26                       56.8               67.9       9                                                 26.2                 8.5                                                 9.0
  Inagaki 2014\[[@pone.0153502.ref062]\]               322                322                 12                       59.8               60.3       6.4                                               25.3                 8.1                                                 9.1
  Iwamoto 2010\[[@pone.0153502.ref063]\]               363                363                 12                       59.8               61.7       5.4                                               24.5                 7.6                                                 8.2
  Kaku 2011\[[@pone.0153502.ref064]\]                  339                339                 52                       60.1               62.8       6.7                                               26.1                 7.9                                                 NR
  Kaku 2011(2)\[[@pone.0153502.ref065]\]               400                400                 52                       58.3               67.3       8.3                                               24.8                 9.3                                                 NR
  Matthews 2010\[[@pone.0153502.ref066]\]              3,118              3,099               104                      57.5               53.5       5.7                                               31.8                 7.3                                                 9.2
  Matyjaszek-Matuszek 2013\[[@pone.0153502.ref067]\]   80                 80                  26                       60                 43.8       8.4                                               32.1                 7.9                                                 9.6
  Mohan 2009\[[@pone.0153502.ref068]\]                 530                530                 18                       50.9               58.0       2.0                                               25.0                 8.7                                                 10.5
  Moses 2014\[[@pone.0153502.ref069]\]                 257                257                 24                       57.0               59.9       NR                                                29.3                 8.3                                                 8.8
  Nauck 2007\[[@pone.0153502.ref070]\]                 1,172              1,172               52                       56.7               59.2       6.4                                               31.2                 7.7                                                 9.2
  Nauck 2009\[[@pone.0153502.ref071]\]                 527                527                 26                       54.8               50.3       6                                                 32                   302(57.3%)[\*\*](#t001fn003){ref-type="table-fn"}   9.5
  Nauck 2013\[[@pone.0153502.ref024]\]                 1,091              1,087               104                      56.7               58.2       7.6                                               31                   8.4                                                 10
  Nonaka 2008\[[@pone.0153502.ref072]\]                151                151                 12                       55.3               63         4                                                 25.2                 7.6                                                 9.1
  Olansky 2011\[[@pone.0153502.ref073]\]               1,246              1,246               44                       49.7               56.5       3.4                                               33.3                 9.9                                                 10.3
  Perez-Monteverde 2011\[[@pone.0153502.ref074]\]      492                452                 40                       51.1               61.0       3.2                                               29.8                 9.1                                                 10.3
  Pfutzner 2011\[[@pone.0153502.ref075]\]              1,306              1,306               76                       52.0               49.2       1.7                                               30.4                 9.5                                                 11.1
  Phillis-Tsimikas 2013\[[@pone.0153502.ref076]\]      447                454                 26                       40.8               58.6       7.8                                               30.4                 8.9                                                 9.6
  Pinget 2013\[[@pone.0153502.ref077]\]                484                484                 24                       55.8               52.3       8.1                                               33.9                 8.1                                                 9.1
  Pratley 2006\[[@pone.0153502.ref078]\]               98                 98                  12                       55.7               42.9       4.3                                               30.0                 8.0                                                 9.6
  Pratley 2009\[[@pone.0153502.ref079]\]               500                500                 26                       56.6               52.2       7.7                                               30.1                 8.1                                                 NR
  Pratley 2009(2)\[[@pone.0153502.ref080]\]            493                493                 24                       55.4               58.2       7.6                                               32.8                 8.0                                                 NR
  Pratley 2013\[[@pone.0153502.ref081]\]               760                751                 24                       56.4               49         8.8                                               32.7                 8.3                                                 10.0
  Prato 2011\[[@pone.0153502.ref082]\]                 503                503                 24                       55.7               48.3       NR                                                29.1                 8                                                   7.1
  Ratner 2010\[[@pone.0153502.ref083]\]                129                129                 12                       57                 14.0       7.0                                               32.4                 7.9                                                 9.1
  Raz 2008\[[@pone.0153502.ref084]\]                   190                190                 30                       54.8               46.3       7.9                                               30.2                 9.2                                                 11.1
  Reasner 2011\[[@pone.0153502.ref085]\]               1,246              1,246               18                       49.7               56.5       3.4                                               33.3                 9.9                                                 12.2
  Riddle 2013\[[@pone.0153502.ref086]\]                495                495                 24                       57                 46         12.5                                              32.1                 8.4                                                 8.0
  Rosenstock 2006\[[@pone.0153502.ref087]\]            353                353                 24                       56.3               55.5       6.1                                               31.5                 8.0                                                 9.3
  Rosenstock 2009\[[@pone.0153502.ref088]\]            598                591                 80                       54.3               56.6       2.2                                               32.6                 8.6                                                 9.9
  Rosenstock 2009(2)\[[@pone.0153502.ref089]\]         390                390                 26                       56.8               41.4       12.6                                              32.5                 9.3                                                 10.6
  Rosenstock 2011\[[@pone.0153502.ref090]\]            859                859                 24                       57.3               50.5       9.3                                               30.2                 8.3                                                 9.5
  Ross 2012\[[@pone.0153502.ref091]\]                  491                491                 12                       58.6               57         227(46.2%)[\*](#t001fn002){ref-type="table-fn"}   29.6                 7.9                                                 9.2
  Russel-Jones 2012\[[@pone.0153502.ref092]\]          820                820                 26                       53.8               59.0       2.7                                               31.2                 8.5                                                 9.9
  Scherbaum 2008\[[@pone.0153502.ref093]\]             131                131                 112                      63.1               59.5       2.3                                               30.3                 6.6                                                 6.9
  Schernthaner 2013\[[@pone.0153502.ref094]\]          755                755                 52                       56.7               55.9       9.6                                               31.6                 8.1                                                 9.3
  Seino 2012\[[@pone.0153502.ref095]\]                 312                312                 64                       60.2               66.7       9.8                                               24.7                 8.6                                                 NR
  Seino 2012(2)\[[@pone.0153502.ref096]\]              288                288                 12                       52.6               68.8       6.3                                               25.9                 8                                                   NR
  Seino 2014\[[@pone.0153502.ref097]\]                 215                212                 16                       57                 69.8       7                                                 25.1                 8.6                                                 NR
  Strain 2013\[[@pone.0153502.ref098]\]                278                278                 24                       74.8               45.3       11.4                                              29.8                 11.4                                                9.8
  Tajima 2011\[[@pone.0153502.ref099]\]                138                138                 12                       60.8               58         9.1                                               24.6                 8.4                                                 8.6
  Tajima 2013\[[@pone.0153502.ref100]\]                133                133                 12                       60.5               65.4       7.2                                               24.1                 7.9                                                 8.4
  Taskinen 2011\[[@pone.0153502.ref101]\]              700                700                 24                       56.5               54         310(44.3%)[\*](#t001fn002){ref-type="table-fn"}   29.9                 8.1                                                 9.4
  Terra 2011\[[@pone.0153502.ref102]\]                 301                301                 12                       56.2               66.4       7.1                                               32.0                 8.3                                                 9.5
  Vilsboll 2010\[[@pone.0153502.ref103]\]              641                641                 24                       57.8               51.0       12.5                                              31.0                 8.7                                                 9.8
  White 2014\[[@pone.0153502.ref104]\]                 160                160                 12                       55.4               53.1       6.0                                               33.1                 7.9                                                 9.1
  Williams-Herman 2009\[[@pone.0153502.ref105]\]       1,091              1,091               54                       53.5               50.6       4.5                                               32.1                 8.8                                                 11.1
  Wysham 2014\[[@pone.0153502.ref106]\]                976                976                 26                       55.6               58.4       9.0                                               33.3                 8.1                                                 9.0
  Yang 2011\[[@pone.0153502.ref107]\]                  570                570                 24                       54.1               48.3       5.1                                               26.2                 7.9                                                 8.8
  **Average value across included trials**             **608**            **610**             **35.1**                 **56.1**           **54.1**   **6.5**                                           **30.3**             **8.3**                                             **9.5**

BMI = body mass index; FPG = fasting plasma glucose; NR = not reported

\* No (%) of patients with no more than 5 years' diabetes duration

\*\* No (%) of patients with HbA1~c~ \< 8%

10.1371/journal.pone.0153502.t002

###### Intervention characteristics of included trials of incretin treatment in patients with type 2 diabetes mellitus.

![](pone.0153502.t002){#pone.0153502.t002g}

  Author (year)                                                  Incretin                      Control     Drugs used across groups   Mode of therapy                                  
  -------------------------------------------------------------- ----------------------------- ----------- -------------------------- ----------------- ------------------------------ --------
  Aschner 2006                                                   sitagliptin                   14/488      placebo                    6/253             none                           mono
  Aschner 2010                                                   sitagliptin                   12/528      metformin                  4/522             none                           mono
  Barnett 2012                                                   saxagliptin                   1/304       placebo                    0/12              insulin ±metformin             add on
  Bergenstal 2009                                                exenatide                     0/124       biphasic insulin aspart    1/248             none                           mono
  Blonde 2009                                                    vildagliptin                  5/1756      thiazolidinediones         1/871             metformin                      add on
  Bolli 2009                                                     vildagliptin                  2/296       pioglitazone               6/280             metformin                      add on
  Bosi 2007                                                      vildagliptin                  6/360       placebo                    3/181             metformin                      add on
  Bosi 2009[\*](#t002fn001){ref-type="table-fn"}                 vildagliptin                  17/879      metformin                  12/292            metformin                      add on
  Chacra 2011                                                    saxagliptin                   92/501      placebo                    45/267            glyburide                      add on
  Del 2011                                                       linagliptin                   21/336      placebo                    6/167             none                           mono
  Dobs 2013                                                      sitagliptin                   2/170       placebo                    0/90              metformin +rosiglitazone       add on
  Filozof 2010                                                   vildagliptin                  36/510      gliclazide                 43/493            metformin                      add on
  Fonesca 2012(2)                                                lixisenatide                  1/239       placebo                    0/122             none                           mono
  Fonseca 2012[^†^](#t002fn003){ref-type="table-fn"}             saxagliptin                   1/238       metformin                  2/144             metformin                      add on
  Fonseca 2013                                                   sitagliptin                   0/157       placebo                    1/156             metformin +pioglitazone        add on
  Forst 2010                                                     linagliptin                   3/197       placebo, glimepiride       0/136             metformin                      add on
  Gallwitz 2012                                                  exenatide                     0/511       glimepiride                4/508             metformin                      add on
  Gallwitz 2012(2)                                               linagliptin                   62/776      glimepiride                86/775            metformin                      add on
  Garber 2007                                                    vildagliptin                  1/304       placebo                    1/158             pioglitazone                   add on
  Garber 2008                                                    vildagliptin                  6/339       placebo                    1/176             glimepiride                    add on
  Garber 2011                                                    liraglutide                   59/497      glimepiride                34/248            none                           mono
  Goke 2013                                                      saxagliptin                   20/428      glipizide                  32/430            metformin                      add on
  Goodman 2009                                                   vildagliptin                  5/248       placebo                    3/122             metformin                      add on
  Grunberge 2012                                                 dulaglutide                   1/132       placebo                    0/32              none                           mono
  Haak 2012[\*](#t002fn001){ref-type="table-fn"}                 linagliptin                   0/428       placebo/metformin          1/429             metformin                      add on
  Henry 2011                                                     saxagliptin                   0/20        placebo                    0/16              none                           mono
  Hollander 2011                                                 saxagliptin                   36/381      placebo                    14/184            thiazolidinediones             add on
  Inagaki 2012                                                   exenatide                     1/215       insulin glargine           0/212             biguanide ±thiazolidinedione   add on
  Inagaki 2014                                                   SYR-472 (DPP-4 inhibitor)     10/266      placebo                    3/55              none                           mono
  Iwamoto 2010                                                   sitagliptin                   3/290       placebo                    0/73              none                           mono
  Kaku 2011                                                      alogliptin                    2/224       placebo                    1/115             pioglitazone                   add on
  Kaku 2011(2)                                                   liraglutide                   34/268      glibendamide               24/132            none                           mono
  Matthews 2010                                                  vildagliptin                  104/ 1553   glimepiride                125/ 1546         metformin                      add on
  Matyjaszek-Matuszek 2013                                       exenatide                     2/40        insulin glargine           0/40              metformin +sulfonylurea        add on
  Mohan 2009                                                     sitagliptin                   1/352       placebo                    0/178             none                           mono
  Moses 2014                                                     saxagliptin                   12/129      placebo                    9/128             metformin +sulfonylurea        add on
  Nauck 2007                                                     sitagliptin                   0/588       glipizide                  2/584             metformin                      add on
  Nauck 2009                                                     alogliptin                    14/423      placebo                    7/104             metformin                      add on
  Nauck 2013                                                     liraglutide                   68/724      glimepiride/ placebo       14/363            metformin                      add on
  Nonaka 2008                                                    sitagliptin                   0/75        placebo                    2/76              none                           mono
  Olansky 2011[^¥^](#t002fn005){ref-type="table-fn"}             sitagliptin                   0/625       placebo                    1/621             metformin other OHA            add on
  Perez-Monteverde 2011[\*\*](#t002fn002){ref-type="table-fn"}   sitagliptin                   1/222       pioglitazone               0/230             metformin                      add on
  Pfutzner 2011[\*](#t002fn001){ref-type="table-fn"}             saxagliptin                   71/978      metformin                  27/328            metformin                      add on
  Phillis-Tsimikas 2013                                          sitagliptin                   0/228       insulin degludec           1/226             metformin                      add on
  Pinget 2013                                                    lixisenatide                  0/323       placebo                    1/161             pioglitazone± metformin        add on
  Pratley 2006                                                   vildagliptin                  6/70        placebo                    6/28              none                           mono
  Pratley 2009                                                   alogliptin                    18/401      placebo                    2/99              glyburide                      add on
  Pratley 2009(2)                                                alogliptin                    19/397      placebo                    1/97              pioglitazone                   add on
  Pratley 2013                                                   taspoglutide                  4/494       pioglitazone               2/257             sulphonylurea ±metformin       add on
  Prato 2011                                                     linagliptin                   21/336      placebo                    6/167             none                           mono
  Ratner 2010                                                    taspoglutide                  0/97        placebo                    1/32              metformin                      add on
  Raz 2008                                                       sitagliptin                   5/96        placebo                    5/94              metformin                      add on
  Reasner 2011[^¥^](#t002fn005){ref-type="table-fn"}             Sitagliptin                   6/625       placebo                    10/621            metformin                      add on
  Riddle 2013                                                    lixisenatide                  1/328       placebo                    0/167             basal insulin ± metformin      add on
  Rosenstock 2006                                                sitagliptin                   1/175       placebo                    0/178             pioglitazone                   add on
  Rosenstock 2009                                                vildagliptin                  46/393      rosiglitazone              27/198            none                           mono
  Rosenstock 2009(2)                                             alogliptin                    1/260       placebo                    0/129             insulin                        add on
  Rosenstock 2011                                                lixisenatide                  1/574       placebo                    0/285             sulfonulurea ± metformin       add on
  Ross 2012                                                      linagliptin                   6/447       placebo                    0/44              metformin                      add on
  Russel-Jones 2012[^ǂ^](#t002fn004){ref-type="table-fn"}        exenatide/ sitagliptin        6/411       pioglitazone/ metformin    15/409            none                           mono
  Scherbaum 2008                                                 vildagliptin                  6/68        placebo                    2/63              none                           mono
  Schernthaner 2013                                              sitagliptin                   0/378       canagliflozin              2/377             metformin +sulfonylurea        add on
  Seino 2012                                                     alogliptin                    2/209       placebo                    0/103             glimepiride                    add on
  Seino 2012(2)                                                  alogliptin                    3/188       placebo                    2/100             metformin                      add on
  Seino 2014                                                     albiglutide                   4/159       placebo                    1/53              none                           mono
  Strain 2013[\*](#t002fn001){ref-type="table-fn"}               vildagliptin                  6/139       placebo                    3/139             sulphonylurea                  add on
  Tajima 2011                                                    sitagliptin                   0/67        placebo                    2/71              glimepiride                    add on
  Tajima 2013                                                    sitagliptin                   1/70        placebo                    0/63              voglibose                      add on
  Taskinen 2011                                                  linagliptin                   17/523      placebo                    6/177             metformin                      add on
  Terra 2011                                                     PF-734200 (DPP-4 inhibitor)   2/225       placebo                    1/76              metformin                      add on
  Vilsboll 2010                                                  sitagliptin                   0/322       placebo                    2/319             insulin ± metformin            add on
  White 2014                                                     saxagliptin                   3/74        placebo                    2/86              metformin                      add on
  Williams-Herman 2009[\*](#t002fn001){ref-type="table-fn"}      sitagliptin                   1/551       Placebo, metformin         1/540             metformin                      add on
  Wysham 2014                                                    dulaglutide/exenatide         1/835       placebo                    0/141             metformin + pioglitazone       add on
  Yang 2011                                                      saxagliptin                   11/283      placebo                    19/287            metformin                      add on

\*: Not all but some treatment groups were co-administered with metformin or sulfonylurea.

\*\*: metformin was co-administered from the start of phase B

^†^: metformin was uptitrated in control group where we defined these treatment arms as add-on therapy, and mentioned metformin as drug used across groups

^ǂ^: Among 4 study groups in this study, we reconstructed the study population and lumped exenatide and sitagliptin group as 'incretin' and pioglitazone and metformin group as 'non-incretin comparator'.

^¥^: incretin groups consisted fixed dose combination formulation with metformin

FDC: fixed-dose combination, OHA: oral hyperglycaemic agent

+: both A and B, -: either A or B, ±: A with or without B, /: A,B consists each separate arm

The heterogeneity between included trials was low according to both of the statistics tests we used (I^2^ = 2%, χ^2^ test = 74.12 \[p = 0.44\]). Seven studies had a prospective independent clinical event committee (CEC), which reviewed and adjudicated events suspected to be CV outcomes.

The shape of Begg's funnel plot ([S2 Fig](#pone.0153502.s002){ref-type="supplementary-material"}) showed only minor asymmetry (with or without inclusion of the studies lacking individual participant data), and Egger's test for asymmetry was not significant (P = 0.14). Thus a publication bias mechanism was not considered a major cause for concern in our study.

Of the 75 randomized controlled trials reporting predefined CV outcomes, only one study stated that no events of CV disease occurred during the course of study \[[@pone.0153502.ref021]\]. In total, 27,764 patients were recruited in intervention groups reporting 924 CV events (3.3%), and 17,884 patients were recruited in control group reporting 641 CV events (3.6%). Two out of 75 included trials, both with DPP-4 inhibitors, independently showed statistical significance in lowering CV risk \[[@pone.0153502.ref022], [@pone.0153502.ref023]\], and one GLP-1 receptor agonist study, in which liraglutide was added to metformin, showed statistical significance in increased CV risk \[[@pone.0153502.ref024]\].

In our primary analysis, pooled estimates of 75 studies showed no significance in beneficial effect of all incretin versus control (M-H OR 0.90, 95% CI 0.81--1.00) on CV risk ([Fig 2](#pone.0153502.g002){ref-type="fig"}). Evaluated as a subgroup, DPP-4 inhibitors alone were mildly protective compared to control (M-H OR 0.87, 95% CI 0.78--0.98), whereas the subgroup including only GLP-1 agonist showed no evidence of protection (M-H OR 0.98, 95% CI 0.76--1.27) ([Fig 3](#pone.0153502.g003){ref-type="fig"}) (χ^2^ test for subgroup differences, p-value = 0.41).

![Risk of cardiovascular events between patients with type 2 diabetes mellitus with no other complications treated with incretin or control.](pone.0153502.g002){#pone.0153502.g002}

![Subgroup analysis by types of incretin therapy.](pone.0153502.g003){#pone.0153502.g003}

Also when we explored the sources of heterogeneity by type of control and mode of therapy, incretin therapy showed beneficial effect in comparison to an active comparator in add-on therapy (M-H OR 0.83, 95% CI 0.71--0.96). Whereas no such effect was observed in placebo-controlled trials and active-controlled mono therapy trials ([S3 Fig](#pone.0153502.s003){ref-type="supplementary-material"}) (χ^2^ test for subgroup differences, p-value = 0.10).

In subgroup analysis by type of 8 predefined CV outcome, no significant effect of incretin was observed in any. In case of death and heart failure, there were many cells with zero events and the maximum number of events per arm was 3, resulting in a small number of total reports and a wide confidence interval ([S4 Fig](#pone.0153502.s004){ref-type="supplementary-material"}) (χ^2^ test for subgroup differences, p-value = 0.35).

The subgroup analysis by type of individual incretins did not show difference among those agents except for vildagliptin, of which showed CV protective effect (M-H OR 0.82,95% CI 0.68--0.99) ([S5 Fig](#pone.0153502.s005){ref-type="supplementary-material"}) (χ^2^ test for subgroup differences, p-value = 0.72).

After performing the subgroup analyses to detect heterogeneity, we found that only two variables in all separate analyses displayed high heterogeneity (p-value lower than 0.1): the 'other/non-specified' subgroup by classification of predefined CV outcome, and the 'liraglutide' subgroup by individual incretin agent analysis. We performed a sensitivity analysis on these two subgroups using random-effect model and the results were consistent.

Discussion {#sec013}
==========

Main findings {#sec014}
-------------

This meta-analysis included a comprehensive search for all trials with incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) for type 2 diabetes treatment. The wide-ranging search allowed separate analyses by type of incretin, type of control and mode of therapy, classification of CV outcome and individual incretin agent.

The overall heterogeneity was low, including all subgroup analyses performed in the present study, which allowed us to apply a fixed-effect model rather than a random-effect model for data pooling.

Overall, incretin-based therapies showed a trend towards lower risk of cardiovascular disease compared to placebo or other antihyperglycemic agents, although the difference was not statistically significant.

The subgroup analysis by type of incretin showed statistical significance between groups; the effect of DPP-4 inhibitors on overall reduction of CV risk was greater than that of GLP-1 receptor agonists. These results suggest that, although drugs may share the pharmacological mechanism of increasing incretin activity, they may have different effects on CV risks. Contrary to our results, a retrospective analysis of the insurance claims database showed lower risk of CV events and hospitalizations in treatment with exenatide twice daily therapies than other-glucose lowering therapies \[[@pone.0153502.ref025]\].

Interestingly, incretin-based therapies were associated with a reduction of CV risk when compared to active antihyperglycemic agents treated in add-on therapies, whereas this effect disappeared when including placebo-comparator trials. Most of the trials in this group (79%) were DPP-4 inhibitors in combination with metformin compared to thiazolidinediones and sulfonylureas. It suggests incretin-based therapies added to metformin or other antihyperglycemic agents (as it is frequently used as second line therapy in treatment of T2DM) have beneficial effects on decreasing CV risks.

No additional effect was found in the subtypes of CV outcomes. Considering that we excluded a number of trials with baseline CV risks in patient characteristics, we infer that incretin-based therapies are associated with lower risk of major CV events, such as cardiac death and heart failure, in primary prevention group patients with low CV risk. Yet, as we collected safety outcomes reported from each study, which incorporates signs and symptoms that are not always a specific diagnosis, definitions of specific major CV events may have varied across studies.

In addition, three individual incretin agents, alogliptin, albiglutide, and liraglutide had higher odds of overall CV risk than comparators, but this difference was not statistically significant. However, vildagliptin was suggested to have a lower risk of CV disease with borderline significance (OR 0.82, 95% CI 0.68 to 0.99), which is consistent with the results from pooled data of 25 phase 3 trials assessing cardio-cerebrovascular safety of vildagliptin \[[@pone.0153502.ref026]\].

Comparison with other studies {#sec015}
-----------------------------

The available evidence regarding incretin-based therapies association with CV risk is currently contradictory. The reports indicate either a detrimental or a beneficial effect. Here we review several studies according to their study design.

Preclinical data indicated a potential cardio protective effect of DPP-4 inhibitors by increasing the concentration not only of GLP-1, but of other vasoactive peptides as well \[[@pone.0153502.ref027]\]. Some evidence shows that GLP-1 might have beneficial effects on the myocardium and on endothelial function \[[@pone.0153502.ref028]\] and GLP-1 has been found to be cardio protective in experimental models of heart failure and myocardial infarction \[[@pone.0153502.ref029]\].

Epidemiologic study data have shown the opposite results of our study, suggesting that exenatide reduces CV disease events (myocardial infarction, ischemic stroke, or coronary revascularization procedure) \[[@pone.0153502.ref025]\] and sitagliptin increases the risk of CV disease related hospital admissions and deaths \[[@pone.0153502.ref030]\]. But in both studies, when history of CV disease was measured, 50 to 60% of included patients with hypertension and dyslipidemia apart from our included patient group. And also both these studies were retrospective database analyses performed using insurance claim data, which are known to have substantial limitations such as misclassification of exposure and outcome using ICD codes mapping.

Patient level results from all completed phase 2/ 3 studies of liraglutide, alogliptin and vildaglipitin respectively showed no relevant significant effect on CV events \[[@pone.0153502.ref026], [@pone.0153502.ref031], [@pone.0153502.ref032]\].

Since US FDA now requires all new antidiabetic agents to undergo a thorough long-term CV risk assessment\[[@pone.0153502.ref008]\], recently four large-scale trials designed for this purpose in incretin have been carried out and currently there are many trials still ongoing expected to be published in forthcoming years (i.e CAROLINA, EXSCEL, LEADER and et cet.).

SAVOR TMI-53 included 16,492 patients with a history of, or at risk of CV events and they were randomly assigned to receive saxagliptin or placebo for an average of 2.1 years. The overall hazard ratio was 1.00 (95% CI 0.89--1.12), but the risk of hospitalization for heart failure was significant (hazard ratio 1.27, 95% CI 1.07--1.51) \[[@pone.0153502.ref009]\].

In the alogliptin trial (Examination of Cardiovascular Outcomes with Alogliptin vs. Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome, EXAMINE), where 5,380 patients were randomly assigned to receive alogliptin or placebo for a median of 18 months after an episode of acute myocardial infarction or unstable angina. The hazard ratio was 0.96 (upper boundary of the one-sided repeated confidence interval, 1.16) \[[@pone.0153502.ref033]\].

In the TECOS (cardiovascular outcomes trial of sitagliptin in T2DM), 14,671 patients were assigned to a group where either sitagliptin or placebo were added to their existing therapy, the median follow-up was 3 years. The trial achieved its primary endpoint of noninferiority for the composite CV endpoint of CV-related death, non-fatal myocardial infarction, non-fatal stroke, or unstable angina requiring hospitalization.---\[[@pone.0153502.ref011]\]. The observation that sitagliptin therapy was not associated with a change in long-term rates of cardiovascular events is consistent with the findings from shorter-term outcome trials of other DPP-4 inhibitors, including the above mentioned saxagliptin and alogliptin.

Last, but most recently, first GLP-1 receptor agonist CV outcome trial result was published which met the pre-specified criterion of non-inferiority versus placebo for the composite primary endpoint of CV death, non-fatal MI, non-fatal stroke and hospitalization for unstable angina (HR 1.02, 0.89--1.17) \[[@pone.0153502.ref012]\] (Lixisenatide CV outcome trial was published in December 2015. As our search includes records up to August 2014, this was not included in current meta-analysis. Only included in the discussion upon reviewer's request).

In randomized controlled CV outcome trials, the patient inclusion criteria were history of established CV disease or multiple CV risk factors. All asserted such criteria because it is known that the risk of CV disease is 2 to 4 times higher in people with diabetes\[[@pone.0153502.ref034]\]. However, it is also known that diabetes substantially increases the risk of major CV complications with and without an established CV disease. Our study focused on the primary prevention patient group with low CV risk. This may explain the differences in results.

Two other meta-analyses have assessed the risk of CV disease among patients using incretins, both examining DPP-4 inhibitors. In the first meta-analysis, overall risk of acute heart failure was higher in patients treated with DPP-4 inhibitors compared to placebo or active comparators (M-H OR: 1.19 (95% CI 1.03--1.37) \[[@pone.0153502.ref035]\]. However, SAVOR TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus- Thrombolysis in Myocardial Infarction trial) trial \[[@pone.0153502.ref009]\] accounted for almost two thirds of all included events in this meta-analysis for heart failure, which raises question because SAVOR was large CV outcome trial resulting in safety concerns regarding possible elevated risk in hospitalization for heart failure. Therefore, this might have affected the results of our study suggesting a higher OR in the DPP-4 group.

Another DPP-4 inhibitor meta-analysis included 70 trials, enrolling 41,959 patients with a mean follow-up of 44.1 weeks. The MH-OR was 0.71 (95% CI 0.59--0.86), 0.64 (95% CI 0.44--0.94), 0.77 (95% CI 0.48--1.24) and 0.60 (95% CI 0.41--0.88) for major adverse cardiovascular events (MACE), myocardial infarction, stroke and mortality, respectively. Treatment with DPP4-inhibitors was suggested to reduce the risk of CV events (particularly myocardial infarction) and all-cause mortality in patients with T2DM \[[@pone.0153502.ref036]\]. The result showed a similar trend of lowering CV risk in DPP-4 inhibitors as our study but had statistical significance. This study had no further restrictions in baseline CV risk, and primary endpoint was only MACE and it also used clinicaltrials.gov as data source. These may have affected difference in included studies and difference in statistical significance.

The heterogeneity of results across meta-analyses or pooled analyses could depend on differences across studies in trial inclusion criteria, definition of events and event adjudication. With respect to pooled analyses of patient-level data, which are available only for each compound separately, the present meta-analysis has the advantage of integrating results for the whole class, thus increasing sample size and statistical power.

Limitations {#sec016}
-----------

The primary limitation of this study is that the analysis was executed on summaries of trial results because original source data at patient-level were not available. This prevented the use of potentially more informative descriptions of events. Some of the adverse events reported were aggregated in the study result, for example, reported as non-specified CV disorder, vascular disease, etc. This may had effect in underestimating subgroup analysis of classified CV outcomes. Also, when screening patients with other comorbidities at baseline, we used patient baseline characteristics described in main result only. This practice may not have sufficiently ruled out trials with CV risk patients in the baseline. Similarly, we only included trials explicitly reporting a number of CV adverse events. Thus studies suggesting safety results without specific numbers for each treatment arm, such as 'cardiovascular event was similar in both groups' were omitted. In addition, we only gathered information on reported adverse events and we did not focus on the change of cardiovascular markers.

A further limitation is that it is possible that a publication bias affected this analysis, although the funnel plot did not show = significant asymmetry. We did not look for unpublished studies through other sources, so publication bias remains a relevant issue in this review.

Long term safety is of particular concern, the need for long term data on CV outcomes is especially important given the concerns with thiazolidinediones, but trials included had relatively short durations. Mean duration of included studies were 35 weeks, ranging from 12 to 112 weeks, but 70% of the trials included lasted for less than 30 weeks.

Most of the studies included were not primarily aimed at CV end-points. In addition, most trials did not centrally adjudicate CV outcomes. For this reason, a method for assessing CV events was not clearly specified in most instances, and definitions of specific CV events may have differed across studies. In many cases, events were not described in published reports or only available in online supplements. However, we made a persistent effort to collect CV outcomes and excluding patients with underlying disease or any other complications.

Conclusion {#sec017}
==========

In conclusion, the results of this meta-analysis suggest that incretin-based therapy show no significant protective effect on CV events in T2DM primary prevention group with low CV risks.

Current evidence is however, not definitive and associations in prospective long-term safety controlled trials are required to clearly determine the risk/benefit ratio for incretin-based therapies.
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